Tools and Technologies I |
Jeanne Loring |
The Stem Cell Matrix: a map of the molecular pathways that define pluripotent cells |
$1,133,552 |
Early Translational III |
Peter Schultz |
Targeting Stem Cells to Enhance Remyelination in the Treatment of Multiple Sclerosis |
$2,559,333 |
New Faculty I |
Kristin Baldwin |
Generating pluripotent cell lines from neurons. |
$2,786,560 |
Transplantation Immunology |
Nicholas Gascoigne |
Role of Innate Immunity in hematopoeitic stem cell-mediated allograft tolerance |
$1,705,554 |
Creativity Awards |
James Williamson |
Stem Cell Summer Academy: Creating the Next Generation of Scientists |
$205,122 |
Quest - Discovery Stage Research Projects |
Stuart Lipton |
Drug Development for Autism Spectrum Disorder Using Human Patient iPSCs |
$1,827,576 |
Early Translational II |
Peter Schultz |
Cartilage Regeneration by the Chondrogenic Small Molecule PRO1 during Osteoarthritis |
$6,047,249 |
Transplantation Immunology |
Jeanne Loring |
Thymus based tolerance to stem cell therapies |
$1,108,921 |
New Cell Lines |
Sheng Ding |
Derivation of New ICM-stage hESCs |
$936,973 |
Discovery Research Projects |
Stuart Lipton |
Repurposing Aminoadamantane Nitrate Compounds to Inhibit SARS-CoV-2 Viral Activity and to Protect the Brain from Viral-Related Damage |
$150,000 |
SEED Grant |
Peter Schultz |
A Chemical Approach to Stem Cell Biology |
$748,944 |
Shared Labs |
Sheng Ding |
TSRI Center for hESC Research |
$1,440,164 |
Research Training Grant |
Peter Schultz |
Training Scholars in Regenerative Medicine and Stem Cell Research |
$4,931,353 |
Early Translational I |
Jeanne Loring |
Ensuring the safety of cell therapy: a quality control pipeline for cell purification and validation |
$5,830,771 |
Basic Biology III |
Joel Gottesfeld |
Triplet Repeat Instability in Human iPSCs |
$1,705,494 |
New Faculty I |
Sheng Ding |
Reprogramming of human somatic cells back to pluripotent embryonic stem cells |
$1,393,876 |
Quest - Discovery Stage Research Projects |
Luke Lairson |
Improving the efficacy and tolerability of clinically validated remyelination-inducing molecules using developable combinations of approved drugs |
$1,554,126 |
Early Translational I |
Martin Friedlander |
Autologous Retinal Pigmented Epithelial Cells Derived from Induced Pluripotent Stem Cells for the Treatment of Atrophic Age Related Macular Degeneration |
$5,806,321 |
Basic Biology III |
Kristin Baldwin |
Identifying sources of mutation in human induced pluripotent stem cells by whole genome sequencing |
$1,705,500 |
Tools and Technologies III |
Jeanne Loring |
User-friendly predictive molecular diagnostic assays for quality control of stem cell derivatives for transplantation and drug discovery |
$1,728,390 |
Quest - Discovery Stage Research Projects |
Michael Bollong |
Therapeutics to overcome the differentiation roadblock in Myelodysplastic Syndrome (MDS) |
$1,244,160 |
Shared Labs |
Jeanne Loring |
TSRI Center for hESC Research |
$3,725,070 |
Research Training II |
Ulrich Mueller |
Training Stem Cell Researchers at the Chemistry-Biology Interface |
$3,697,326 |
Quest - Discovery Stage Research Projects |
Jeanne Loring |
Autologous cell therapy for Parkinson’s disease using iPSC-derived DA neurons |
$2,299,786 |
Quest - Discovery Stage Research Projects |
Stuart Lipton |
Drug Development of Inhibitors of Inflammation Using Human iPSC-Derived Microglia (hiMG) |
$1,658,123 |
Tools and Technologies I |
Carlos Barbas |
Development of a novel technology for precise, efficient, and safe genetic modification of stem cells |
$1,138,548 |
Training Grant I-2 |
Peter Schultz |
Training Grant I |
$1,021,395 |
Conference |
Jeanne Loring |
World Stem Cell Summit |
$30,000 |
New Faculty I |
Kristin Baldwin |
Generating pluripotent cell lines from neurons. |
$2,786,560 |